1. Market Research
  2. > Pharmaceutical
  3. > OTC Market Trends
  4. > EpiCast Report: Insomnia - Epidemiology Forecast to 2023

EpiCast Report: Insomnia - Epidemiology Forecast to 2023

  • February 2015
  • -
  • Global Data
  • -
  • 67 pages

EpiCast Report: Insomnia - Epidemiology Forecast to 2023

Summary

GlobalData epidemiologists forecast that the total prevalent cases of acute insomnia in the 7MM will increase from 121,799,911 total prevalent cases in 2013, to 130,482,156 total prevalent cases in 2023 at an Annual Growth Rate (AGR) of 0.71%. GlobalData epidemiologists forecast an increase in the total prevalent cases of chronic insomnia (not fulfilling DSM-IV criteria) in the 7MM from 62,982,390 total prevalent cases in 2013, to 67,471,957 total prevalent cases in 2023 at an AGR of 0.71%. The 7MM had an estimated 23,690,040 total prevalent cases of chronic primary insomnia in 2013 and the number of total prevalent cases is expected to increase to 25,378,728 by 2023, at an AGR of 0.71%. GlobalData epidemiologists forecast that the total prevalent cases of chronic secondary insomnia in the 7MM will increase from 53,697,425 total prevalent cases in 2013, to 57,525,122 total prevalent cases in 2023 at an AGR of 0.71%.

Insomnia is a highly prevalent condition; approximately one third of the general population presents with some degree of insomnia.

GlobalData epidemiologists used comprehensive country-specific data from population-based studies published in peer-reviewed journal articles to arrive at a meaningful, in-depth analysis and forecast for the total prevalent cases of acute insomnia, chronic insomnia (not fulfilling DSM-IV criteria), chronic primary insomnia, and chronic secondary insomnia in the 7MM, based on the DSM-IV criteria. For all the 7MM, the total prevalent cases of acute insomnia, chronic insomnia (not fulfilling DSM-IV criteria), chronic primary insomnia, and chronic secondary insomnia were segmented by age and sex, which facilitates an understanding of the distribution of the disease within the population and informs strategies to improve the management of the disease. Furthermore, the forecast methodology is consistent across each of the 7MM, thereby allowing for a meaningful comparison of the forecast total prevalent cases among each market.

Scope

- The Insomnia EpiCast Report providess an overview of the risk factors, comorbidities, and the global and historical trends for insomnia in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for the total prevalent cases of acute insomnia, chronic insomnia (not fulfilling DSM-IV criteria), chronic primary insomnia, and chronic secondary insomnia, segmented by sex and age (in 15-year age groups beginning at 15 years and ending at =75 years) in these markets.
- The insomnia epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy

- Develop business strategies by understanding the trends shaping and driving the global insomnia market.
- Quantify patient populations in the global insomnia market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the sex and age groups that present the best opportunities for insomnia therapeutics in each of the markets covered.

Table Of Contents

EpiCast Report: Insomnia - Epidemiology Forecast to 2023
1 Table of Contents
2 Introduction 10
2.1 Catalyst 10
2.2 Related Reports 11
2.3 Upcoming Related Reports 12
3 Epidemiology 13
3.1 Disease Background 13
3.2 Risk Factors and Comorbidities 13
3.3 Global Trends 14
3.4 Forecast Methodology 16
3.4.1 Sources Used 22
3.4.2 Sources Not Used 23
3.4.3 Forecast Assumptions and Methods 24
3.5 Epidemiological Forecast for Acute Insomnia (2013-2023) 33
3.5.1 Total Prevalent Cases of Acute Insomnia 33
3.5.2 Age-Specific Total Prevalent Cases of Acute Insomnia 35
3.5.3 Sex-Specific Total Prevalent Cases of Acute Insomnia 36
3.5.4 Age-Standardized Total Prevalence of Acute Insomnia 38
3.6 Epidemiological Forecast for Chronic Insomnia (Not Fulfilling DSM-IV Criteria) (2013-2023) 39
3.6.1 Total Prevalent Cases of Chronic Insomnia (Not Fulfilling DSM-IV Criteria) 39
3.6.2 Age-Specific Total Prevalent Cases of Chronic Insomnia (Not Fulfilling DSM-IV Criteria) 40
3.6.3 Sex-Specific Total Prevalent Cases of Chronic Insomnia (Not Fulfilling DSM-IV Criteria) 42
3.6.4 Age-Standardized Total Prevalent Cases of Chronic Insomnia (Not Fulfilling DSM-IV Criteria) 44
3.7 Epidemiological Forecast for Chronic Primary Insomnia (2013-2023) 45
3.7.1 Total Prevalent Cases of Chronic Primary Insomnia 45
3.7.2 Age-Specific Total Prevalent Cases of Chronic Primary Insomnia 46
3.7.3 Sex-Specific Total Prevalent Cases of Chronic Primary Insomnia 48
3.7.4 Age-Standardized Total Prevalence of Chronic Primary Insomnia 50
3.8 Epidemiological Forecast for Chronic Secondary Insomnia (2013-2023) 51
3.8.1 Total Prevalent Cases of Chronic Secondary Insomnia 51
3.8.2 Age-Specific Total Prevalent Cases of Chronic Secondary Insomnia 52
3.8.3 Sex-Specific Total Prevalent Cases of Chronic Secondary Insomnia 54
3.8.4 Age-Standardized Total Prevalence of Chronic Secondary Insomnia 56
3.9 Discussion 57
3.9.1 Epidemiological Forecast Insight 57
3.9.2 Limitations of the Analysis 58
3.9.3 Strengths of the Analysis 59
4 Appendix 60
4.1 Bibliography 60
4.2 About the Authors 62
4.2.1 Epidemiologists 62
4.2.2 Reviewers 62
4.2.3 Global Director of Therapy Analysis and Epidemiology 63
4.2.4 Global Head of Healthcare 64
4.3 About GlobalData 65
4.4 About EpiCast 65
4.5 Disclaimer 66

1.1 List of Tables

Table 1: Risk Factors and Comorbidities for Insomnia 14
Table 2: DSM-IV Diagnostic Criteria for Primary Insomnia 17
Table 3: Sources of Epidemiological Data Used for the Forecast for Total Prevalent Cases of Acute Insomnia in the 7MM 18
Table 4: Sources of Epidemiological Data Used for the Forecast for Total Prevalent Cases of Chronic Insomnia (Not Fulfilling DSM-IV Criteria) in the 7MM 19
Table 5: Sources of Epidemiological Data Used for the Forecast for Total Prevalent Cases of Chronic Primary Insomnia in the 7MM 20
Table 6: Sources of Epidemiological Data Used for the Forecast for Total Prevalent Cases of Chronic Secondary Insomnia in the 7MM 21
Table 7: 7MM, Total Prevalent Cases of Acute Insomnia, Both Sexes, Ages ?15 Years, N, Select Years 2013-2023 34
Table 8: 7MM, Age-Specific Total Prevalent Cases of Acute Insomnia, Both Sexes, N (Row %), 2013 35
Table 9: 7MM, Sex-Specific Total Prevalent Cases of Acute Insomnia, Ages ?15 Years, N (Row %), 2013 37
Table 10: 7MM, Total Prevalent Cases of Chronic Insomnia (Not Fulfilling DSM-IV Criteria), Both Sexes, Ages ?15 Years, N, Select Years 2013-2023 39
Table 11: 7MM, Age-Specific Total Prevalent Cases of Chronic Insomnia (Not Fulfilling DSM-IV Criteria), Both Sexes, N (Row %), 2013 41
Table 12: 7MM, Sex-Specific Total Prevalent Cases of Chronic Insomnia (Not Fulfilling DSM-IV Criteria), Ages ?15 Years, N (Row %), 2013 43
Table 13: 7MM, Total Prevalent Cases of Chronic Primary Insomnia, Both Sexes, Ages ?15 Years, N, Select Years 2013-2023 45
Table 14: 7MM, Age-Specific Total Prevalent Cases of Chronic Primary Insomnia, Both Sexes, N (Row %), 2013 47
Table 15: 7MM, Sex-Specific Total Prevalent Cases of Chronic Primary Insomnia, Ages ?15 Years, N (Row %), 2013 49
Table 16: 7MM, Total Prevalent Cases of Chronic Secondary Insomnia, Both Sexes, Ages ?15 Years, N, 2013-2023 51
Table 17: 7MM, Age-Specific Total Prevalent Cases of Chronic Secondary Insomnia, Both Sexes, N (Row %), 2013 53
Table 18: 7MM, Sex-Specific Total Prevalent Cases of Chronic Secondary Insomnia, Ages ?15 Years, N (Row %), 2013 55

1.2 List of Figures

Figure 1: Global Average of the Total Prevalence of Insomnia Symptoms and Diagnoses 15
Figure 2: Patient Flow for the Epidemiological Forecast of Insomnia in the 7MM 16
Figure 3: 7MM, Total Prevalent Cases of Acute Insomnia, Both Sexes, Ages ?15 Years, N, 2013-2023 34
Figure 4: 7MM, Age-Specific Total Prevalent Cases of Acute Insomnia, Both Sexes, N, 2013 36
Figure 5: 7MM, Sex-Specific Total Prevalent Cases of Acute Insomnia, Ages ?15 Years, N, 2013 37
Figure 6: 7MM, Age-Standardized Total Prevalence of Acute Insomnia (%), Ages ?15 Years, by Sex, 2013 38
Figure 7: 7MM, Total Prevalent Cases of Chronic Insomnia (Not Fulfilling DSM-IV Criteria), Both Sexes, Ages ?15 Years, N, 2013-2023 40
Figure 8: 7MM, Age-Specific Total Prevalent Cases of Chronic Insomnia (Not Fulfilling DSM-IV Criteria), Both Sexes, Ages ?15 Years, N, 2013 42
Figure 9: 7MM, Sex-Specific Total Prevalent Cases of Chronic Insomnia (Not Fulfilling DSM-IV Criteria), Ages ?15 Years, N, 2013 43
Figure 10: 7MM, Age-Standardized Total Prevalence of Chronic Insomnia (Not Fulfilling DSM-IV Criteria) (%), Ages ?15 Years, by Sex, 2013 44
Figure 11: 7MM, Total Prevalent Cases of Chronic Primary Insomnia, Both Sexes, Ages ?15 Years, N, 2013-2023 46
Figure 12: 7MM, Age-Specific Total Prevalent Cases of Chronic Primary Insomnia, Both Sexes, N, 2013 48
Figure 13: 7MM, Sex-Specific Total Prevalent Cases of Chronic Primary Insomnia, Ages ?15 Years, N, 2013 49
Figure 14: 7MM, Age-Standardized Total Prevalence of Chronic Primary Insomnia (%), Ages ?15 Years, by Sex, 2013 50
Figure 15: 7MM, Total Prevalent Cases of Chronic Secondary Insomnia, Both Sexes, Ages ?15 Years, N, 2013-2023 52
Figure 16: 7MM, Age-Specific Total Prevalent Cases of Chronic Secondary Insomnia, Both Sexes, N, 2013 54
Figure 17: 7MM, Sex-Specific Total Prevalent Cases of Chronic Secondary Insomnia, Ages ?15 Years, N, 2013 55
Figure 18: 7MM, Age-Standardized Total Prevalence of Chronic Secondary Insomnia (%), Ages ?15 Years, by Sex, 2013 56

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Sleep Aids: Technologies and Global Markets

Sleep Aids: Technologies and Global Markets

  • $ 6650
  • Industry report
  • October 2016
  • by BCC Research

Use this report to: - Analyze the current market dynamics and evaluate the effect of strategic factors such as technology-driven change and industry consolidation of sleep aids and technologies. - Review ...

Sleeping Aids Market: By Sleep Disorder (Insomnia, Sleep Apnea, Restless Leg Syndrome, Narcolepsy, Sleep Walking) Product (Mattress & Pillow, Sleep Labs, Medication, Sleep Apena Devices) Medication (Prescription Based, OTC drugs, Herbal Drugs)-Forecast (2

Sleeping Aids Market: By Sleep Disorder (Insomnia, Sleep Apnea, Restless Leg Syndrome, Narcolepsy, Sleep Walking) Product (Mattress & Pillow, Sleep Labs, Medication, Sleep Apena Devices) Medication (Prescription Based, OTC drugs, Herbal Drugs)-Forecast (2

  • $ 5250
  • Industry report
  • September 2016
  • by Industry ARC

Sleep aids are pills and medical devices that enable a person suffering from sleep disorder to fall asleep. Sleep aids consist of various products such as medications, sleep laboratories, sleep apnea devices, ...

Global Market Study on Sleep Aids: Sleep Apnea to Witness Highest Growth by 2020

Global Market Study on Sleep Aids: Sleep Apnea to Witness Highest Growth by 2020

  • $ 4900
  • Industry report
  • August 2016
  • by Persistence Market Research

Sleep aids are pills and medical devices which enable a person suffering from sleep disorder to fall asleep. They are used for diagnosis and treatment of sleep disorders and sleep disturbances. Sleep disorders ...

Consumer Health In The Us

September 2016 $ 2423

Consumer Health In Belgium

September 2016 $ 2423

Consumer Health In Austria

September 2016 $ 2423

Consumer Health In Canada

September 2016 $ 2423

Sleep Aids In Egypt

September 2016 $ 912

Sleep Aids In Morocco

September 2016 $ 912

ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.